S81478 |
Monomethyl auristatin E |
源葉(MedMol) | 99% |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.393 ml | 6.964 ml | 13.928 ml |
5 mM | 0.279 ml | 1.393 ml | 2.786 ml |
10 mM | 0.139 ml | 0.696 ml | 1.393 ml |
50 mM | 0.028 ml | 0.139 ml | 0.279 ml |
- 提示:詳情請下載說明書。
- 產(chǎn)品描述: Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types
- 靶點: Auristatin;Apoptosis;?MicrotubuleAssociated
- 體外研究:
Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells
- 體內(nèi)研究:
Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models
- 參考文獻(xiàn):
1. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. 2. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.
- 溶解性: Soluble in DMSO、Ethanol
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 1.393 ml 6.964 ml 13.928 ml 5 mM 0.279 ml 1.393 ml 2.786 ml 10 mM 0.139 ml 0.696 ml 1.393 ml 50 mM 0.028 ml 0.139 ml 0.279 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:
本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)